Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLR325 in Chronic Stable Heart Failure
NCT02696967Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in chronic heart failure (CHF) comparing CLR325 with Placebo (2 arms). Primary endpoint: Number of Patients With Adverse Events, Serious Adverse Events and Death. Started May 2016; status: completed.
02
Drugs
CLR325
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT02696967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02696967.